One of the most common questions patients ask after completing a successful course of transcranial magnetic stimulation (TMS) is: “How do I stay well?” For many individuals with treatment-resistant Depression (TRD), the acute course of TMS produces substantial relief. But Depression is often a recurrent illness, and even patients who achieve remission remain vulnerable to relapse over time.
A 2025 study published in JAMA Network Open, known as the MAINT-R Randomized Clinical Trial, provides some of the strongest evidence to date that maintenance repetitive transcranial magnetic stimulation (rTMS) can help prevent Depression from returning. Led by Yoshihiro Noda and colleagues at Keio University in Tokyo, the study compared low-frequency maintenance rTMS with lithium augmentation, a long-established pharmacologic strategy used to reduce relapse in TRD. The findings are relevant to patients treated at Mid City TMS, where maintenance TMS is an option for individuals who wish to preserve the gains achieved during their initial treatment course.
Why Relapse Prevention Matters in Depression
Major Depressive Disorder is often chronic and recurrent. Even after symptoms improve, the risk of recurrence remains real, especially for people who have failed multiple antidepressant medications, experienced severe or prolonged depressive episodes, or had repeated relapses in the past. Without an effective maintenance strategy, many patients may experience a gradual return of symptoms like low mood, poor motivation, sleep disturbance, and impaired functioning. The challenge in psychiatry is not simply getting patients better; it is keeping them better.
What Is Maintenance TMS?
Maintenance TMS refers to scheduled treatment sessions given after a patient has responded to an initial acute course of TMS. Rather than daily sessions five days a week, patients may receive treatment once weekly, every other week, monthly, or on a personalized schedule based on symptoms and relapse risk. The goal is to reinforce healthy brain circuit activity and prevent depressive symptoms from returning.
Overview of the MAINT-R Trial
The MAINT-R trial enrolled 75 adults with TRD, all of whom had a history of failing at least two adequate antidepressant trials and had already responded to an acute course of bilateral rTMS or bilateral theta-burst stimulation in a related study (BEAT-D). All participants continued a stable dose of venlafaxine (150-225 mg/day) and were randomly assigned to one of two 24-week maintenance strategies: low-frequency rTMS to the right dorsolateral prefrontal cortex (38 participants) or lithium augmentation (37 participants), dosed to a therapeutic blood level of 0.4 to 0.6 mEq/L.
The rTMS protocol used 1 Hz stimulation, 900 pulses per weekly session, at 120% of resting motor threshold, delivered over 15 minutes. This is worth noting explicitly: the acute phase that got these patients into remission used bilateral stimulation, while the maintenance phase tested here switched to lower-frequency, right-side-only stimulation, a different protocol from the higher-frequency left-sided approach more commonly used in acute TMS treatment.
The study’s primary outcome was the difference in depression severity, measured by the Montgomery-Ã…sberg Depression Rating Scale (MADRS), between groups at 24 weeks. Time to relapse and adverse events were tracked as secondary outcomes. The trial was single-blind, meaning the clinicians and patients knew which treatment was assigned, but the raters assessing outcomes were blinded to group assignment throughout the study.
Key Findings
Comparable efficacy. There was no statistically significant difference in the primary outcome measure at 24 weeks between the two groups (a difference of just 0.3 points on the MADRS scale, 95% CI −2.7 to 3.3, P=.84). Relapse rates were nearly identical: 7 of 38 patients relapsed in the rTMS group (18.4%) and 7 of 37 relapsed in the lithium group (18.9%), with no meaningful difference in the survival curves (log-rank P=.92). Notably, both groups relapsed less often than the trial’s own pre-study assumptions predicted; the sample size was originally calculated based on an estimated 65% relapse-prevention success rate for lithium drawn from earlier research, but the lithium group in this trial performed considerably better than that assumption, converging closely with the rTMS group’s outcome.
Dramatically better tolerability. The most striking difference was in adverse events: 3 in the rTMS group compared with 16 in the lithium group, a statistically significant difference (odds ratio 7.10, 95% CI 1.84-27.49, P=.005). The lithium group’s adverse events included tremor, headache, dizziness, insomnia, decreased libido, pancreatitis, and hypertension, in addition to depressive symptoms that didn’t meet the threshold for relapse. One participant in the lithium group required hospitalization for worsening depression, the only serious adverse event reported in the study.
A caveat on the adverse event comparison. The study’s authors are explicit about an important limitation here: routine blood testing, including thyroid function monitoring, was not built into the trial’s adverse event tracking. Since lithium is well known to affect thyroid and kidney function over time, and those effects would not necessarily produce reportable symptoms without lab testing, the study’s authors note that the number of lithium-related adverse events may have been undercounted. The tolerability advantage for rTMS is likely real, but the “3 vs. 16” comparison probably understates the true gap, since testing wasn’t in place to catch everything.
Why This Study Is So Important
Lithium is one of psychiatry’s most evidence-based relapse prevention treatments, but many patients avoid it because of its side effect burden and the need for regular blood monitoring. The MAINT-R study demonstrates that maintenance TMS can provide comparable relapse prevention without those burdens, at least over the six-month window this trial measured. For patients who prefer non-medication approaches, or who are unable to tolerate lithium or other augmenting medications, this is a meaningful finding.
Advantages of Maintenance TMS
- Noninvasive. TMS uses magnetic pulses applied to the scalp and does not require surgery or anesthesia.
- No systemic side effects. Unlike medications, TMS does not cause weight gain, sexual dysfunction, or gastrointestinal problems.
- No routine laboratory monitoring. Maintenance TMS does not require blood tests or medication level checks.
- Personalized scheduling. Treatment frequency can be adjusted to each patient’s clinical course.
- Preserves previous gains. Maintenance sessions help reinforce the same neural circuits that improved during the acute course.
Limitations of the MAINT-R Trial
Several limitations are worth knowing about before drawing strong conclusions. The trial’s sample size, while it met its pre-specified target of 72 participants, was calculated using assumptions borrowed from other studies in different populations, a method the authors themselves describe as exploratory. Follow-up lasted only 24 weeks, so longer-term relapse risk beyond six months was not assessed. The protocol tested a specific approach, low-frequency, right-sided rTMS, which differs from the higher-frequency, often left-sided approaches used in other TMS research, so these findings may not generalize to every maintenance protocol.
The study was single-blind rather than placebo-controlled, and while outcome raters were blinded, patients and treating clinicians knew their assignment, which can introduce some bias. The lithium group also had, on average, roughly two years longer illness duration than the rTMS group, a baseline difference the study’s randomization method did not fully control for. Finally, the trial was conducted entirely in Japan with an almost entirely Japanese participant population, which may limit how well the findings generalize to other populations.
It’s also worth noting that the study received funding and equipment support from Teijin Pharma and Magventure, a TMS device manufacturer, and several co-authors reported financial relationships with TMS device companies, which is common in device research but worth knowing about.
Despite these limitations, the study represents meaningful randomized evidence supporting maintenance TMS as a real option for relapse prevention.
How Mid City TMS Uses Maintenance Treatment
At Mid City TMS, we recognize that successful Depression treatment extends past the initial acute course. For patients who respond well to TMS, we often develop individualized maintenance plans based on prior history of relapse, severity and chronicity of illness, degree of improvement during acute treatment, ongoing stressors, and patient preference. Some individuals benefit from once or twice monthly booster sessions, while others may need more frequent treatment initially and taper over time.
Who May Benefit Most From Maintenance TMS?
Maintenance TMS may be particularly useful for patients who achieved significant benefit from acute TMS, have recurrent or chronic Depression, experienced multiple prior relapses, prefer to minimize medication exposure, cannot tolerate lithium or other augmentation strategies, or want a proactive relapse-prevention plan.
Final Thoughts on Maintenance TMS for Depression
The 2025 MAINT-R trial offers real evidence that maintenance TMS is an effective and better-tolerated strategy for preventing relapse in treatment-resistant Depression, at least over a six-month period and within the specific low-frequency, right-sided protocol tested. Weekly low-frequency rTMS performed comparably to lithium, with substantially fewer reported adverse events, though the true safety gap may be even larger than the numbers suggest given the study’s monitoring limitations. For patients who have achieved relief through TMS, this study offers real reassurance that ongoing booster treatments can be part of a plan to maintain wellness.
If you have benefited from TMS or are considering treatment for Depression that has not responded to medication, learn how Mid City TMS can help and contact us today to discuss whether maintenance TMS is right for you.
Sources
- Noda Y, Wada M, Mimura Y, et al. Repetitive Transcranial Magnetic Stimulation as Maintenance Treatment of Depression: The MAINT-R Randomized Clinical Trial. JAMA Netw Open. 2025;8(6):e2515881. doi:10.1001/jamanetworkopen.2025.15881